

Oxygen and mortality in COVID-19 pneumonia: a comparative analysis of supplemental oxygen policies and health outcomes across 26 countries.

Goyal D, Donnelly H, Kussner A, Neil J, Bhatti S and Mansab F.

Daniel K Goyal, MRCP, PhD, COVID-19 Public Health Team, Public Health Gibraltar, Gibraltar & Clinical Lecturer, University of Gibraltar, GX11 1AA
Corresponding Author: daniel.goyal@gha.gi

Harry Donnelly, MBBS, Acute General Medicine, St Bernard's Hospital, Gibraltar Health Authority

Albrecht Kussner, MRCP, Emergency Medicine, St Bernard's Hospital, Gibraltar Health Authority, Gibraltar

James Neil. PhD (Computer Science). Centre for Nutrition Education and Lifestyle Management (CNELM), London, UK

Sohail Bhatti, FRSPH, Director of Public Health Gibraltar & Head of School of Postgraduate Medicine, University of Gibraltar

Fatma Mansab, MSc Immunology, COVID-19 Public Health Team, Public Health Gibraltar & Clinical Lecturer, University of Gibraltar

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

ABSTRACT

Introduction

Hypoxia is the main cause of morbidity and mortality in COVID-19. During the COVID-19 pandemic some countries have reduced access to supplemental oxygen (e.g. oxygen rationing), whereas other nations have maintained and even improved access to supplemental oxygen. We examined whether such variation in the access to supplemental oxygen had any bearing on mortality in COVID-19.

Methods

Three independent investigators searched for, identified and extracted the nationally recommended target oxygen levels for the commencement of oxygen in COVID-19 pneumonia from the 29 worst affected countries. Mortality estimates were calculated from three independent sources. We then applied linear regression analysis to examine for potential association between national targets for the commencement of oxygen and case fatality rates.

Results

Of the 26 nations included, 15 had employed conservative oxygen strategies to manage COVID-19 pneumonia. Of them, Belgium, France, USA, Canada, China, Germany, Mexico, Spain, Sweden and the UK guidelines advised commencing oxygen when oxygen saturations (SpO₂) fell to 91% or less. Target SpO₂ ranged from 92% to 95% in the other 16 nations. Linear regression analysis demonstrated a strong inverse correlation between the national target for the commencement of oxygen and national case fatality rates (Spearman's Rho = -0.622, $p < 0.001$).

Conclusion

Our study highlights the disparity in oxygen provision for COVID-19 patients between the nations analysed, and indicates such disparity in access to supplemental oxygen may represent a modifiable factor associated with mortality during the pandemic.

Key Messages

What is already known?

- There were no prospective clinical trials we could identify relating to COVID-19 and supplemental oxygen, nor any published studies examining access to supplemental oxygen and mortality in COVID-19.
- There are a number of studies identifying an association with low oxygen saturations at presentation and mortality in COVID-19 pneumonia.
- There is good quality evidence that a delay in the correction of hypoxia in pneumonia increases mortality.

What are the new findings?

- This study highlights the different thresholds for commencing supplemental oxygen in patients with COVID-19 across 26 nations.
- Those countries that provide better access to supplemental oxygen have a statistically significant lower mortality rate.
- Our results support the consensus view that improving access to supplemental oxygen in COVID-19 pneumonia is likely to reduce mortality.

Introduction

SARS-CoV2 causes COVID-19 (Coronavirus Disease 2019). As of May 2020, the total reported cases of COVID-19 was over 5 million, with 350,000 deaths over five months[1]. More than half these deaths have occurred in the last month. Whilst there has been a slight reduction in the rate of growth for new infections globally, this is most likely due to strict infection control policies (e.g. case-isolation, social distancing and ‘lockdown’)[2]. With the seroprevalence of SARS-CoV2 being reported as between <1% to 22%[3], it is most likely the majority of infections are yet to come, and the rate of infections will once again increase as infection control measures are balanced with economic pressures.

The true COVID-19 mortality rate is difficult to ascertain during the outbreak. Background infections, asymptomatic infections, testing criteria, reporting of fatalities and the time-lag between new cases and outcome are all potential confounders[4]. This makes measuring the effects of national interventions difficult. It is though, reasonable to expect a nation’s COVID-19 mortality rate will depend on access to healthcare, and likely will also depend on the type of healthcare offered. The need for effective healthcare can be reasonably inferred from the marked disparity between mortality rates during a surge of cases versus mortality post-surge[5].

Oxygen is a cornerstone of treatment for patients with COVID-19 pneumonia. Indeed, the major mechanism for injury and death in COVID-19 relates to hypoxia[6]. Despite the critical nature of oxygen therapy in COVID-19 pneumonia there remains marked variation between national guidelines for when to offer supplemental oxygen. Many nations seem to have implemented conservative oxygen strategies during the pandemic, effectively limiting the access of patients to supplemental oxygen. Others seem to have actively increased their capacity to offer supplemental oxygen for patients with COVID-19 pneumonia. Here, we examine the national guidelines from 29 nations in an effort to understand the potential impact the varying thresholds for commencing supplemental oxygen have on COVID-19 outcomes.

Methods

We followed the advice for global reporting on health estimates as per the GATHER statement[7]. All countries with more than 20,000 cases as of 18/05/20, were assessed. Three investigators independently identified the specific national recommendations for the target oxygen saturations (SpO₂) to commence oxygen in patients with COVID-19. Two investigators were blinded as to the reason for the study. Each nation’s ministry of health, national guideline bodies, respiratory medicine bodies and national health service were searched for relevant COVID-19 clinical guidelines. The European Society of Respiratory Medicine was a useful resource with direct links to a number of COVID-19 specific clinical guidelines from across the world. Literature databases were also used as a means of identifying links to national guidelines. If guidelines were not available in one of the languages spoken by the investigators, on-line translation services were utilised, specifically for guidelines on ‘supplemental oxygen’ or ‘oxygen therapy’ - the entire guideline was not translated. Note, only guidelines applicable to the majority of the population were extracted, and guidelines for patients with underlying conditions such as chronic obstructive airways disease were not recorded.

If guidelines were unclear, instruction was to disregard the country from further analysis. Where there were more than one recommendation the investigator was to make a determination as to the most likely guideline to be followed (figure 1). Where there was divergence between the three investigators, the consensus value was used. Results were tabulated and compared.

Case Fatality Rate and Infection Fatality Rate

Case Fatality Rate (CFR) is the percentage ratio of deaths to total cases. It is a crude figure privy to a number of potential confounders. For most nations it is likely to be numerically incorrect[4]. CFR is though, likely to maintain a relationship to actual infection mortality rate (IFR)[3,4], and as such was used in this study. CFR was calculated and cross-referenced from three different sources - The WHO, John Hopkins University and Worldometer. There was no significant difference between the calculated CFR across the three sources.

Patient and Public Involvement

It was not possible to include patients or public in the present study.

Statistical Analysis

Linear regression was performed to identify a potential trend between CFR and Target SpO₂, and presented using scatter-plots. Due to the sample size (n=26), it was not clear whether the assumptions of normality and linearity were met, so the statistical significance of the possible relationship between CFR and target SpO₂ was established using the non-parametric Spearman's-Rho test. We have also explored the effect of potentially confounding variables using the non-parametric Spearman's-rho test rather than using a parametric Mancova test to adjust for confounding, given the small sample size and uncertainty regarding linearity and normality.

Results

In total there were 29 countries with total case numbers over 20,000 on 18th May 2020. Of those, 26 countries had accessible clinical guidelines referring to target oxygen levels for the commencement of supplemental oxygen in COVID-19. UAE (United Arab Emirates) was excluded from further analysis as the national guidelines advised (at page 9) admitting all patients with COVID-19 to hospital, and commencing oxygen when 'needed'[8] - the country's low CFR is noted. The Netherlands and Belarus were also excluded due to all three investigators failing to find clear national guidelines regarding oxygen targets.

Of the remaining 26 countries there was concordance between all three investigators identifying the same national target oxygen levels in 23 countries. Of the remaining 3 countries (UK, Pakistan and Qatar), determination of national target SpO₂ in COVID-19 was made by consensus. For links to national guidelines please see Supplementary File.

Of the 26 nations analysed, six recommended commencing oxygen if SpO₂ fell to below 95% (Singapore, Peru, Switzerland, Ireland, Qatar and Pakistan), five made recommendation for Below 94% (Saudi Arabia, Chile, Brazil, India and Russia), five for

below 93% (Portugal, Iran, Turkey, Bangladesh and Italy), six for below 92% (Canada, Belgium, France, UK, USA and China) and four for below 91% (Germany, Mexico, Spain and Sweden). CFR ranged from 0.06% (Qatar) to 16.4% (Belgium). There was a strong inverse correlation between recommended target oxygen saturations and national case fatality rates ($r_s = -0.622$, $p < 0.001$). A scatter graph with linear best-fit line is at Figure 2.




Figure 2. Scatter graph of national target oxygen saturations versus national case fatality rate with best fit linear line (n=26). SpO2 - oxygen saturations.

Confounders

National guidelines for target saturations were relatively clear for most countries. Together with the high rate of consensus amongst investigators it seems unlikely that investigator bias was a significant factor. The main confounders are more likely to stem from the many variables associated with CFR.

We found no correlation between CFR and cases/million inhabitants (Figure 3B), or tests/thousand inhabitants (Figure 3C), or overall positivity rate (Figure 3C), suggesting testing strategy between the countries examined did not have a significant visible relationship with our mortality measure, CFR (Table 1). We could not examine the potential impact of national-level reporting bias on the CFR from the data available.




Figure 3. Scatter graphs with best-fit line for primary measure and confounders versus CFR (N= 26). CFR is along the horizontal axis in each and measured in percentage. A) Comparison of national CFR versus nationally recommended target SpO2 (%) in COVID-19. B) CFR versus burden of cases measured by total number of cases per million. C) CFR versus Testing Rate measured by total number of tests undertaken per thousand inhabitants (tests/ thousand). D) CFR versus the overall positivity ratio (%), measured as the percentage ratio of positive tests to total tests.
CFR - Case Fatality Rate; SpO2 - oxygen saturations. CFR - Case Fatality Rate; SpO2 - Oxygen Saturations.

	SpO2	Tests per Thousand	Positivity Ratio	Case Burden	CFR
	(%)		(%)	(cases/ million)	(%)
Qatar	94	82.3	25.9	20311	0.06
Singapore	94	57.2	10.5	6036	0.08
Pakistan	94	2.6	12.9	329	2.1
Peru	94	33.2	15.8	5163	2.8
Switzerland	94	46.3	7.7	3569	6.1
Ireland	94	70.6	7.7	5080	6.4
Saudi Arabia	93	24.6	10.6	2506	0.79
Russia	93	76.4	3.8	2843	0.9
Chile	93	32.1	17.5	5505	1
India	93	2.9	5.2	144	3.1
Brasil	93	4.4	56.9	2492	6.9
Bangladesh	92	2.0	15.4	301	1.5
Turkey	92	24.9	7.9	1955	2.8
Portugal	92	83.0	4	3206	4.2
Iran	92	11.6	16.1	1841	6
Italy	92	65.5	6	3857	14
China	91	N/A	N/A	N/A	5.6
USA	91	56.2	10.2	5620	6
Canada	91	45.7	5.4	2431	7.3
UK	91	68.0	6.4	4072	14.4
France	91	21.2	13.7	2899	15.2
Belgium	91	76.3	6.7	5051	16.4
Germany	90	47.1	4.6	2194	4.5
Spain	90	86.9	7	6133	10
Mexico	90	2.2	34.4	725	10.5
Sweden	90	27.3	15.8	3746	10.9
Correlation with CFR (Spearman's Ro)	-0.622	0.0658	-0.13	0.018	
2-tailed (p-value)	<0.001	0.75	0.54	0.93	

Table 1. National CFR, target SpO2 and potential testing confounders in 26 countries. CFR - Case Fatality Rate; SpO2 - Oxygen Saturations. Overall Positivity Ratio- percentage ratio of positive to total cases; Case Burden - total number of positive cases per million inhabitants. Data extracted from WHO, Worldometer and John Hopkins University.

Discussion

National guidelines for when to commence supplemental oxygen in patients with COVID-19 varied significantly between the countries examined. Combined, the target SpO₂ for the *commencement* of oxygen and target SpO₂ for ongoing treatment varied from 90% to 98%. Countries that implemented conservative oxygen strategies in response to the pandemic - effectively limiting access to supplemental oxygen - had statistically significant higher case fatality rates. There are a number of potential reasons for the variation in oxygen policies between countries and the association with mortality.

Causative effect

It has been established that a delay in identifying and correcting hypoxia in pneumonia leads to increased disease severity, increased rate of mechanical ventilation and increased mortality[9,10]. Whilst there are no controlled studies in COVID-19 specifically examining duration spent hypoxic and subsequent disease burden and mortality, Sun et al., has reported a reduction in the need for mechanical ventilation where hypoxia was detected and corrected early in patients with COVID-19[11].

In relation to conservative oxygen strategies generally, there are four key mortality studies. The IOTA meta-analysis published in 2018 examined conservative versus liberal oxygen strategies across a range of studies. Whilst none of the studies analysed in the IOTA meta-analysis related to pneumonia, and the majority of studies examined oxygen as a treatment *not* as a means to correct hypoxia, the authors suggest optimal target SpO₂ for all acute medical patients might be 94-96%[12].

Since the IOTA study, there have been three clinical studies, two of which were randomised controlled trials (RCT), examining the mortality effect of conservative oxygen. The ICU-ROX trial suggests there may be no mortality effect at the higher target levels of SpO₂ (96-97% versus 95-96%) in mechanically ventilated patients from any cause (n=1000)[13]. Another, retrospective analysis, published in March 2020 examined over 35,000 intensive care patients and found the optimum SpO₂ target of 94-98%. The authors note that patients who were in the optimal range for only 40% of the time had nearly twice the mortality of those who spent 80% of the time within the optimal target[14].

The most recent RCT, and the most well-controlled study of true conservative oxygen strategies to date (and the most relevant to COVID-19), examined 204 patients with acute respiratory distress syndrome (ARDS). Patients were randomised to either a conservative arm (actual SpO₂ of 92-93%) versus a liberal arm (SpO₂ of 95-97%), and then followed up for 90 days. The study was halted early due to excessive deaths in the conservative oxygen group, with a 27% increase in intensive care deaths and a 50% increase in 90 day mortality[15].

Based on our current understanding of the affects of hypoxia on inflammation[16] and coagulation[17], there is good scientific basis for the increased mortality associated with sub-optimal oxygen strategies and/or a delay in correcting hypoxia. There are direct effects of hypoxia leading to increased mortality, such as cardiac arrhythmias and ischaemic related pathologies (as identified in the aforementioned ARDS study[15]). It is also quite plausible, indeed quite likely, given that hypoxia is pro-inflammatory, the delay in correcting hypoxia leads to more severe disease. This of course raises the possibility that rationing, or a conservative oxygen approach, or a failure to provide access to supplemental oxygen in COVID-19 pneumonia, actually increases healthcare burden and resource consumption.

Whilst sometimes arguably unavoidable, the decision to limit access to supplemental oxygen should be undertaken mindful of the likely mortality impact, and of the possibility of perpetuating a healthcare crisis. Implementing oxygen early is likely to prevent disease progression, as suggested by Sun et al. [11], and as is consistent with established practice relating to pneumonia generally [9,10].

Resource limitations

For some nations there was a resource limitation issue, or at least a fear of resource limitation, with secondary implementation of conservative oxygen strategies. For example, the UK directive to ration oxygen supply in April 2020 reduced the normal national target for the commencement of oxygen from SpO₂ of 94% to a new value of 91%. The reason for rationing was related to the surge of infections and subsequent concern over the supply of oxygen[18]. If such practises are common in other nations, the relationship between national guidelines' SpO₂ and national CFR identified here may be a representation of the demands on healthcare during a surge of COVID-19 cases.

There are a number of reasons why mortality increases during a surge of infections. Patients are less likely to attend hospital or seek medical care, either for fear of contracting COVID-19 or over-burdening their health service[19]. Triage systems during a surge can be set with high thresholds for onward referrals[20]. Another mortality factor is a potential lack of resources both staff and consumables. The overall delay to treatment that ensues prevents early correction of hypoxia, implementation of VTE (venous thromboembolism) prophylaxis, readjustment of medications (e.g. nephrotoxics) and the detection of secondary bacterial infection, and thus a likely increased mortality[21]

So then, the association between target SpO₂ and CFR identified here may be more related to target SpO₂ being an indicator of an overwhelmed healthcare service. If this is the case, a lower than usual target SpO₂ may still contribute to the higher mortality experienced in nations that suffered an overwhelming surge. In a UK cohort, during the initial surge of infections, and during oxygen rationing, approximately 62% of patients presented hypoxic, and of those that died 75% (60/80) of patients presented hypoxic (defined broadly in this study as SpO₂ <95%)[22]. In a cohort from Mexico, 96% of the patients who died presented with SpO₂ under 88%[23].

Part of the increased mortality seen during a surge of infections may be related to the secondary conservative oxygen policies and delay in correction of hypoxia.

National Approach

The issuing of national guidelines recommending lower target oxygen saturations than would be typical for viral pneumonias[24], may relate more to the overall approach of a national response to COVID-19, and as such, it is this 'national approach' that relates to mortality rate.

All three investigators noted the quite different approaches between nations, as set out in their national guidelines. Some followed a 'stay home' approach, whereas others defaulted to clinical assessment of patients either with COVID-19 or with any risk factor associated with it. For example, Singapore guidelines default to clinical assessment[25], whereas a country with a similar prevalence burden, the UK, has much higher thresholds for referral onward for assessment[26] (Table 2).

	Singapore	UK
Criteria for Clinical Assessment		
SpO2 (%)	< 95	< 92
Age (yrs)	> 65	Irrelevant
Co-morbidity	Any	Severe
Duration of illness (days)	> 3	Irrelevant
Epidemiology		
Cases/million inhabitants	6,063	4,076
Physicians/10,000 head of capita	24	28
CFR (%)	0.08	13.4

Table 2. Comparison of the Criteria for Assessment in suspected or confirmed COVID-19 between Singapore and the UK. Information is based on the clinical guidelines from each nation and WHO (see Supplementary File). SpO2 - oxygen saturations. CFR - case fatality rate.

In this situation, where the national guideline target SpO2 is part of an overall strategy of avoiding admissions, then whilst it does remain likely conservative oxygen approaches do contribute to higher mortality, there may also be contribution of other policies. In the UK versus Singapore example, a target SpO2 of less than 92% is likely to be harmful, but equally, failing to account for age of the patient or duration of fever may also be harmful. As such, the relationship identified here between CFR and target SpO2 may be more a relationship between CFR and national strategy. Target SpO2 may be more of an indicator of national policy.

Limitations

This study highlights the variation in national guidelines for when to commence supplemental oxygen in patients with COVID-19. In of itself, this raises important questions as to the optimal response to COVID-19. Attempting to delineate the interventions and strategies that are potentially beneficial between nations is difficult without using a mortality estimation, which carries inherent confounders. CFR depends on many factors, not least of which is the accurate reporting of COVID-19 related deaths. Whilst we found no correlation between CFR and rates of testing or crude case burden, we could not account for disparities in reporting of deaths. We were aware of this limitation prior to the study, but agreed with the view that while CFR is unlikely to be numerically correct, the difference between countries will remain[3,4], and as such the association is likely to be accurate.

We undertook an analysis of the national guidelines using three independent investigators. The consensus amongst the investigators supports the accuracy of the target SpO2

extracted. The possibility remains that localities within a country, or individual doctors and nurses, chose not to follow their national guidelines. Even if such local differences were significant, the national guidelines *permits* not implementing oxygen therapy until the target oxygen level is reached, therefore triage systems, nurses and physicians can avoid admissions, and thus limit access to supplemental oxygen. Despite the prospect of local variations in following the guidelines, the presence of the guidelines will shape and likely reflect practice nationally.

Conclusion

There is clear disparity between national guidelines for target oxygen saturations (SpO₂) in COVID-19 across the countries analysed here, and such disparity is associated with national case fatality rates (CFR). Whilst there are multiple confounders to the CFR, the overall relationship between increasing CFR with a decreasing target SpO₂ is likely real. The cause for the relationship may be a true causative effect of hypoxia on mortality. It may also be an indirect effect of delayed or reduced access to supplemental oxygen stemming from an overwhelmed or under-resourced health service, or, a similar policy-related reduction in access to supplemental oxygen associated with the differing overall national approaches to COVID-19 - stay home versus clinical assessment. All three possibilities highlighted here implicate delayed initiation of oxygen in the excess mortality associated with COVID-19.

Further research is needed to explore the population risk associated with delayed correction of hypoxia in COVID-19. Additionally, it would be useful to undertake a health-risk analysis, from a resource allocation perspective, on the benefits of increasing access to supplemental oxygen for patients with COVID-19 versus other interventions. As it stands currently, our results support the position that managing COVID-19 pneumonia should not differ from the management of other pneumonias, in so much as, access to supplemental oxygen is necessary to prevent excessive mortality.

Conflicts

The authors declare no conflicts of interests

Contribution

DG, HD, AK, JN, SB and FB contributed to the conception and/or design of the study and contributed to the manuscript. DG, HD and FB conducted the analysis of the national guidelines. Statistical analysis was undertaken primarily by JN. DG wrote the majority of the manuscript. SB and FB undertook final edits. All contributors reviewed the final manuscript before submission.

REFERENCES

1. WHO Situation Report 119, May 18th 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200518-covid-19-sitrep-119.pdf?sfvrsn=4bd9de25_4
2. Okell LC, Verity R, Watson OJ, et al. Have deaths from COVID-19 in Europe plateaued due to herd immunity? [published online ahead of print, 2020 Jun 11]. *Lancet*. 2020;395(10241):e110-e111. doi:10.1016/S0140-6736(20)31357-X
3. Ioannidis J. The infection fatality rate of COVID-19 inferred from seroprevalence data. *medRxiv* 2020.05.13.20101253; doi: <https://doi.org/10.1101/2020.05.13.20101253> PREPRINT - Not Peer reviewed.
4. Battegay M, Kuehl R, Tschudin-Sutter S, Hirsch HH, Widmer AF, Neher RA. 2019-novel Coronavirus (2019-nCoV): estimating the case fatality rate - a word of caution. *Swiss Med Wkly*. 2020;150:w20203. Published 2020 Feb 7. doi:10.4414/smw.2020.20203
5. Ji Y, Ma Z, Peppelenbosch MP, Pan Q. Potential association between COVID-19 mortality and health-care resource availability. *Lancet Glob Health*. 2020;8(4):e480. doi:10.1016/S2214-109X(20)30068-1
6. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in *Lancet*. 2020 Mar 28;395(10229):1038] [published correction appears in *Lancet*. 2020 Mar]
7. Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. *Lancet*. 2016;388(10062):e19-e23. doi:10.1016/S0140-6736(16)30388-9
8. United Arab Emirates Ministry of Health and Prevention. National Guidelines for Clinical Management and Treatment of COVID-19. April 3rd, 2020, Version 2. <https://www.dha.gov.ae/en/HealthRegulation/Documents/COVID%20National%20Guidelines%20FINAL%2018%20March.pdf>
9. Hu WP, Zhang FY, Zhang J, et al. Initial diagnosis and management of adult community-acquired pneumonia: a 5-day prospective study in Shanghai. *J Thorac Dis*. 2020;12(4):1417-1426. doi:10.21037/jtd.2020.03.02
10. Blot SI, Rodriguez A, Solé-Violán J, et al. Effects of delayed oxygenation assessment on time to antibiotic delivery and mortality in patients with severe community-acquired pneumonia. *Crit Care Med*. 2007;35(11):2509-2514. doi:10.1097/01.CCM.0000287587.43801.9C
11. Sun Q, Qiu H, Huang M, Yang Y. Lower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu Province. *Ann Intensive Care*. 2020;10(1):33. Published 2020 Mar 18. doi:10.1186/s13613-020-00650-2
12. O'Driscoll BR, Howard LS, Earis J, Mak V; British Thoracic Society Emergency Oxygen Guideline Group; BTS Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. *Thorax*. 2017;72(Suppl 1):ii1-ii90. doi:10.1136/thoraxjnl-2016-209729
13. Chu DK, Kim LH, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. *Lancet*. 2018;391(10131):1693-1705. doi:10.1016/S0140-6736(18)30479-3
14. Van den Boom W, Hoy M, Sankaran J, et al. The Search for Optimal Oxygen Saturation Targets in Critically Ill Patients: Observational Data From Large ICU Databases. *Chest*. 2020;157(3):566-573. doi:10.1016/j.chest.2019.09.015
15. Barrot L, Asfar P, Mauny F, et al. Liberal or Conservative Oxygen Therapy for Acute Respiratory Distress Syndrome. *N Engl J Med*. 2020;382(11):999-1008. doi:10.1056/NEJMoa1916431
16. Fröhlich S, Boylan J, McLoughlin P. Hypoxia-induced inflammation in the lung: a potential therapeutic target in acute lung injury?. *Am J Respir Cell Mol Biol*. 2013;48(3):271-279. doi:10.1165/rcmb.2012-0137TR
17. Børvik T, Evensen LH, Morelli VM, Melbye H, Brækkan SK, Hansen JB. Impact of respiratory symptoms and oxygen saturation on the risk of incident venous thromboembolism-the Tromsø study. *Res Pract Thromb Haemost*. 2020;4(2):255-262. Published 2020 Jan 9. doi:10.1002/rth2.12299
18. NHS England. Clinical guide for the optimal use of Oxygen therapy during the coronavirus pandemic. 9 April 2020 Version 1. <https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/04/C0256-specialty-guide-oxygen-therapy-and-coronavirus-9-april-2020.pdf>

19. Lee SA, Mathis AA, Jobe MC, Pappalardo EA. Clinically significant fear and anxiety of COVID-19: A psychometric examination of the Coronavirus Anxiety Scale [published online ahead of print, 2020 May 20]. *Psychiatry Res.* 2020;290:113112. doi:10.1016/j.psychres.2020.113112
20. Steinberg E, Balakrishna A, Habboushe J, Shawl A, Lee J. Calculated decisions: COVID-19 calculators during extreme resource-limited situations. *Emerg Med Pract.* 2020;22(4 Suppl):CD1-CD5. Published 2020 Apr 6.
21. Goyal DK, Mansab F, Iqbal A, Bhatti S. Early intervention likely improves mortality in COVID-19 infection [published online ahead of print, 2020 May 1]. *Clin Med (Lond).* 2020;clinmed.2020-0214. doi:10.7861/clinmed.2020-0214
22. Kenneth F. Baker, Aidan T. Hanrath, Ina Schim van der Loeff et al., COVID-19 management in a UK NHS Foundation Trust with a High Consequence Infectious Diseases centre: a detailed descriptive analysis *medRxiv* 2020.05.14.20100834; <https://doi.org/10.1101/2020.05.14.20100834>. PREPRINT - not peer reviewed yet.
23. Soto-Mota, Braulio A. Marfil Garza, Erick Martinez Rodriguez et al., The Low-HARM score for predicting mortality in patients diagnosed with COVID-19: a multicentre validation study. *medRxiv* 2020.05.26.20111120 <https://doi.org/10.1101/2020.05.26.20111120> PREPRINT - not peer reviewed yet.
24. British Thoracic Society 2015 - Annotated BTS Guideline for the management of CAP in adults (2009). <https://www.brit-thoracic.org.uk/quality-improvement/guidelines/pneumonia-adults/>
25. National Centre for Infectious Diseases (Singapore), Interim Treatment Guidelines for COVID-19 (Version 1.0, dated 2 April 2020) <https://www.ncid.sg/Health-Professionals/Diseases-and-Conditions/Documents/Treatment%20Guidelines%20for%20COVID-19%20%282%20Apr%202020%29%20-final.pdf>
26. NICE (UK) guideline [NG165] COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community Published date: 03 April 2020 - <https://www.nice.org.uk/guidance/ng165>

Supplementary File

Oxygen and mortality in COVID-19 pneumonia: a comparative analysis of supplemental oxygen policies and health outcomes across 26 countries.

Goyal D, et al.,

	Target O2 Sats	Link to National Guidelines All viewed between 18th May 2020 and 6th June 2020
Pakistan	94%	Government of Pakistan - guidelines for all patients with COVID-19 http://covid.gov.pk/new_guidelines/05June2020_20200106_Clinical_Management_Guidelines_for_COVID-19_infection_v2.pdf
Singapore	94%	National Centre for Infectious Diseases, Singapore - guidelines for all patients with COVID-19 https://www.ncid.sg/Health-Professionals/Diseases-and-Conditions/Documents/Treatment%20Guidelines%20for%20COVID-19%20%282%20Apr%202020%29%20-final.pdf
Swiss	94%	Swiss Society of Intensive Care, published in Swiss Medical Weekly DOI: https://doi.org/10.4414/smw.2020.20227 Publication Date: 24.03.2020 Applies to all adult patients with COVID-19 https://smw.ch/article/doi/smw.2020.20227
Ireland	94%	Irish Thoracic Society. https://irishthoracicsociety.com/wp-content/uploads/2020/03/COVID-Respiratory-Management-Guideline09.04.20.pdf
Qatar	94%	Ministry of Public Health, Qatar https://ddc.moph.gov.qa/viralpneumonia/eng/file/guidelines/g_CPG.pdf
Saudi Arabia	93%	Ministry of Health, Kingdom of Saudi Arabia https://www.moh.gov.sa/Ministry/MediaCenter/Publications/Documents/Coronavirus-Disease-2019-Guidelines-v1.2.pdf
Chile	93%	RECOMENDACIONES CLÍNICAS DE KINESIOLOGÍA RESPIRATORIA EN ATENCIÓN DE PACIENTES CON COVID-19 Sociedad Chilena de Kinesiología Respiratoria (SOCHIKIR) Sociedad Argentina de Kinesiología Cardio Respiratoria (SAKICARE) División de Kinesiología Intensiva, Sociedad Chilena de Medicina Intensiva (DIKISOCHIMI) https://www.researchgate.net/publication/340608875_Guia_de_recomendaciones_clinicas_de_kinesiologia_respiratoria_en_atencion_de_pacientes_con_COVID-19
India	93%	INTERNATIONAL PULMONOLOGIST'S CONSENSUS ON COVID-19 https://www.unah.edu.hk/dmsdocument/9674-consenso-internacional-de-neumologos-sobre-covid-19-version-ingles
Portugal	92%	SOCIEDADE PORTUGUESA DE PNEUMOLOGIA RECOMENDAÇÕES DA SPP SOBRE TERAPIAS RESPIRATÓRIAS NÃO-INVASIVAS EM CONTEXTO DE DOENTE AGUDO/CRÓNICO AGUDIZADO NA COVID-19 https://www.sppneumologia.pt/uploads/subcanais_conteudos_ficheiros/terapias_spp.pdf

	Target O2 Sats	Link to National Guidelines All viewed between 18th May 2020 and 6th June 2020
Turkey	92%	Turkey Ministry of Health COVID-19 (SARS-CoV2 ENFEKSİYONU) REHBERİ, March 2020 https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf Page 23
Italy	92%	Italian Thoracic Society (AIPO - ITS) and Italian Respiratory Society (SIP/IRS), March 2020 AIPO Managing the Respiratory care of patients with COVID-19.pdf https://ers.app.box.com/s/j09ysr2kdhmkcuiulm8y8dxnosm6yi0h
UK	91%	1. NHS England. Clinical guide for the optimal use of Oxygen therapy during the coronavirus pandemic. 9 April 2020 Version 1. https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/04/C0256-specialty-guide-oxygen-therapy-and-coronavirus-9-april-2020.pdf 2. National Institute of Clinical Guidelines, UK - https://www.nice.org.uk/guidance/ng165
Belgium	91%	Institute of Tropical medicine Antwerp INTERIM CLINICAL GUIDANCE FOR ADULTS WITH SUSPECTED OR CONFIRMED COVID-19 IN BELGIUM Accessed 20/05/20 https://covid-19.sciensano.be/sites/default/files/Covid19/COVID-19_InterimGuidelines_Treatment_ENG.pdf
France	91%	Pneumology and Respiratory Intensive Care Department, Dijon University Hospital Center, Dijon, France Procedure for the pulmonary management of non-ICU patients hospitalized in the context of the COVID-19 pandemic http://splf.fr/wp-content/uploads/2020/04/RespiPreREA-SPLF-GAVO2avril2020-english-version-r.pdf
Canada	91%	Government of Canada Clinical management of patients with moderate to severe COVID-19 - Interim guidance https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/clinical-management-covid-19.html#5
Peru	94%	Society of Pneumologia, Peru Lineamientos de manejo hospitalario del paciente con COVID-19, 28.MARZO.2020. http://www.spneumologia.org.pe https://drive.google.com/file/d/1VQk7Vo8mLJ4ilMekFzsW4rUOPIRy-8wX/view
Brasil	93%	GRUPO FORÇA COLABORATIVA COVID-19 BRASIL Orientações sobre Diagnóstico, Tratamento e Isolamento de Pacientes com COVID-19. Versão 01 Data: 13/04/2020
Germany	90%	German Society of Medical Intensive Care and Emergency Medicine German recommendations for critically ill patients with COVID-19 https://pneumologie.de/fileadmin/user_upload/COVID-19/German_recommendations_for_critically_ill_patients_with_COVID-19_MKIM_2019.pdf
Iran	92%	Health and Treatment Deputy of the Ministry of Health and Medical Education (2020). Guideline for the diagnosis and treatment of COVID-19 in outpatients and inpatients. http://dme.behdasht.gov.ir/uploads/Felo_Tashkish.pdf
Bangladesh	92%	Disease Control Division Directorate General of Health Services Ministry of Health & Family Welfare Government of the People's Republic of Bangladesh National Guidelines on Clinical Management of Coronavirus Disease 2019 (Covid-19) Version 4.0 30 March 2020 http://www.mohfw.gov.bd/index.php?option=com_docman&task=doc_download&gid=22424&lang=en
China	91%	Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). <i>Mil Med Res.</i> 2020;7(1):4. Published 2020 Feb 6. doi:10.1186/s40779-020-0233-6
USA	91%	Poston JT, Patel BK, Davis AM. Management of Critically Ill Adults With COVID-19. <i>JAMA.</i> Published online March 26, 2020. doi:10.1001/jama.2020.4914

	Target O2 Sats	Link to National Guidelines All viewed between 18th May 2020 and 6th June 2020
Spain	90%	SOCIEDAD ESPAÑOLA DE NEUMOLOGÍA Y CIRUGÍA TORÁCICA FISIOTERAPIA RESPIRATORIA EN EL MANEJO DEL PACIENTE CON COVID-19: RECOMENDACIONES GENERALES Spain - http://svmeft.com/wp-content/uploads/2020/03/COVID19-SEPAR-26_03_20.pdf http://svmeft.com/wp-content/uploads/2020/03/COVID19-SEPAR-26_03_20.pdf
Mexico	90%	Government of Mexico https://coronavirus.gob.mx/wp-content/uploads/2020/04/Flujograma_Atencion_Primer_Nivel_13042020.pdf
Sweden	90%	Drug Therapeutic Committee and the Health and Medical Care Administration of the Stockholm County Council, Sweden https://janusinfo.se/behandling/akutinternmedicin/infektionssjukdomar/infektionssjukdomar/covid19infektion.5_5d5ae8ba1719cea8d541290e.html#h-Skyddsutrustninginomsjukvarden
Russia	93%	Ministry of Health ПРОФИЛАКТИКА, ДИАГНОСТИКА И ЛЕЧЕНИЕ НОВОЙ КОРОНАВИРУСНОЙ ИНФЕКЦИИ https://static-1.rosminzdrav.ru/system/attachments/attaches/000/050/116/original/28042020_MR_COVID-19_v6.pdf

Supplementary Table 1. Target oxygen saturations with links to national guidelines.

